Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune announced positive topline results from its Phase 2 Lauriet study of semorinemab, an anti-Tau monoclonal antibody for mild-to-moderate Alzheimer’s disease (AD). The study achieved a 43.6% reduction in cognitive decline at week 49 as measured by the ADAS-Cog11 scale, confirming the treatment's efficacy across various subgroups. However, it did not meet the second co-primary endpoint related to daily living activities. Safety results were positive, indicating semorinemab had an acceptable safety profile with no unexpected adverse events. The ongoing open-label study aims to further assess long-term effects.
AC Immune SA (NASDAQ: ACIU) reported progress in its clinical trials and financial results for Q3 2021, achieving its first positive cognitive results for a Tau-targeting monoclonal antibody in Alzheimer’s disease. The Phase 2 Lauriet trial showed a statistically significant 43.6% reduction in cognitive decline. The company enhanced its portfolio through the acquisition of an alpha-synuclein vaccine candidate. Financially, AC Immune holds CHF 188.6 million in cash, sufficient to fund operations through Q1 2024, despite a net loss of CHF 15.9 million for the quarter.
AC Immune SA (NASDAQ: ACIU), a biopharmaceutical company based in Switzerland, is extending its research partnership with the University of Pennsylvania focused on TDP-43 proteinopathies. The collaboration aims to explore the mechanisms of TDP-43 misfolding and cell-to-cell transmission, which are important in neurodegenerative diseases like ALS and Alzheimer's. The initial research demonstrated distinct TDP-43 species affecting disease progression. AC Immune is also advancing its lead anti-TDP-43 antibody and developing a PET tracer for diagnostics.
AC Immune SA (NASDAQ: ACIU) announced the presentation of new data on its Alzheimer’s disease candidates at the upcoming Clinical Trials on Alzheimer’s Disease (C-TAD) Conference in Boston from November 9-12, 2021. Highlights include:
- Semorinemab: Phase 2 trial results presented on November 10.
- ACI-35.030: Interim Phase 1b/2a data on safety presented on November 12.
- ACI-24: Phase 2 study results from November 9-12.
This continues AC Immune's focus on neurodegenerative diseases with a pipeline of clinical candidates.
AC Immune (NASDAQ: ACIU) has appointed Dr. Monica Shaw and Prof. Monika Bütler to its Board of Directors following an extraordinary general meeting (EGM). They replace Mr. Martin Velasco and Dr. Peter Bollmann. Dr. Shaw brings extensive drug development experience, while Prof. Bütler contributes expertise in economics and public policy. Both express enthusiasm about advancing AC Immune's mission in precision medicine for neurodegenerative diseases like Alzheimer’s. The company has a strong pipeline and partnerships that may enhance shareholder value.
AC Immune SA (NASDAQ: ACIU) announced participation in the Jefferies London Healthcare Conference on November 18-19, 2021. CEO Prof. Andrea Pfeifer will lead a fireside chat discussing the company’s corporate strategy, focusing on precision medicine and ongoing clinical trials, including the Lauriet Phase 2 trial of semorinemab for Alzheimer’s disease. The fireside chat will be available on-demand during the conference and later on AC Immune’s website. The company continues to advance its pipeline aimed at treating neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) announced that its Co-Founder and CEO, Andrea Pfeifer, received the SEF.WomenAward for CEO of the Year at the Swiss Economic Forum on September 2, 2021. The award acknowledges the exemplary entrepreneurial achievements of women. Pfeifer emphasized the importance of recognizing talent in the field of neurodegenerative diseases, stating that their work, alongside pharmaceutical partners, aims to advance a diversified pipeline targeting these critical health challenges. AC Immune focuses on personalized medicine for conditions like Alzheimer’s and Parkinson’s.
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical firm, has announced its participation in several upcoming virtual investor conferences. Key events include the Citi’s 16th Annual BioPharma Virtual Conference on September 8 and Morgan Stanley’s 19th Annual Global Healthcare Conference on September 10. During these conferences, CEO Prof. Andrea Pfeifer will present the company’s corporate strategy and discuss its clinical-stage vaccine programs targeting neurodegenerative diseases. A webcast of the presentations will be available on AC Immune’s website.
AC Immune SA (NASDAQ: ACIU) announced that the Phase 2 Lauriet trial of semorinemab in mild-to-moderate Alzheimer's disease met one co-primary endpoint, ADAS-Cog11, showing a 43.6% reduction in cognitive decline compared to placebo (p0.0025). However, the second endpoint, ADCS-ADL, was not met, and no significant effects were seen on other cognitive measures. The safety profile of semorinemab was consistent with prior studies. Genentech will continue the open label portion of the trial, with top-line results scheduled for presentation at the CTAD conference in November 2021.
AC Immune SA (NASDAQ: ACIU) announced a strategic acquisition of the PD01 vaccine candidate for Parkinson's disease and secured investments from prominent backers of BioNTech SE. With a robust cash position of CHF 199.1 million, the company is financed through at least Q1 2024. Recent clinical results for ACI-24 demonstrated immunogenicity in Down syndrome-related Alzheimer’s, while the Phase 1b/2a anti-pTau trial has been expanded with promising interim results. However, the company reported a net loss of CHF 19.1 million for Q2 2021.